Case Report: Durable Partial Response to Icotinib Plus Crizotinib in a Lung Adenocarcinoma Patient with Double Uncommon EGFR G719D/L861Q Mutations and an Acquired Novel CUX1-MET Fusion
Frontiers in oncology(2022)
Key words
lung adenocarcinoma,EGFR mutations,CUX1-MET fusion,icotinib plus crizotinib,partial response
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined